Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer.
Cancer
Epigenetics
Genetics
Oncology
Telomeres
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
received:
15
12
2020
accepted:
16
09
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Aberrant activation of telomerase in human cancer is achieved by various alterations within the TERT promoter, including cancer-specific DNA hypermethylation of the TERT hypermethylated oncological region (THOR). However, the impact of allele-specific DNA methylation within the TERT promoter on gene transcription remains incompletely understood. Using allele-specific next-generation sequencing, we screened a large cohort of normal and tumor tissues (n = 652) from 10 cancer types and identified that differential allelic methylation (DAM) of THOR is restricted to cancerous tissue and commonly observed in major cancer types. THOR-DAM was more common in adult cancers, which develop through multiple stages over time, than in childhood brain tumors. Furthermore, THOR-DAM was especially enriched in tumors harboring the activating TERT promoter mutations (TPMs). Functional studies revealed that allele-specific gene expression of TERT requires hypomethylation of the core promoter, both in TPM and TERT WT cancers. However, the expressing allele with hypomethylated core TERT promoter universally exhibits hypermethylation of THOR, while the nonexpressing alleles are either hypermethylated or hypomethylated throughout the promoter. Together, our findings suggest a dual role for allele-specific DNA methylation within the TERT promoter in the regulation of TERT expression in cancer.
Identifiants
pubmed: 34720085
pii: 146915
doi: 10.1172/JCI146915
pmc: PMC8553568
doi:
pii:
Substances chimiques
DNA, Neoplasm
0
Neoplasm Proteins
0
TERT protein, human
EC 2.7.7.49
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : U01 CA074783
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167551
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074783
Pays : United States
Organisme : CIHR
ID : MOP-137899
Pays : Canada
Références
J Invest Dermatol. 2016 Jan;136(1):339-342
pubmed: 26763461
Nature. 2007 Aug 16;448(7155):767-74
pubmed: 17700693
Science. 2013 Feb 22;339(6122):959-61
pubmed: 23348503
Oncogene. 2002 Aug 12;21(35):5380-7
pubmed: 12154400
Genes (Basel). 2016 Aug 18;7(8):
pubmed: 27548225
Cell Oncol (Dordr). 2020 Oct;43(5):847-861
pubmed: 32468444
Nat Rev Genet. 2010 May;11(5):319-30
pubmed: 20351727
Cancer Sci. 2008 Aug;99(8):1528-38
pubmed: 18754863
Neuroepidemiology. 2012;39(2):116-24
pubmed: 22846789
Onco Targets Ther. 2016 Jan 11;9:279-86
pubmed: 26834487
Oncotarget. 2016 Sep 6;7(36):57726-57736
pubmed: 27437772
Cell. 2013 Jan 31;152(3):390-3
pubmed: 23374336
Rev Urol. 2005;7 Suppl 3:S11-8
pubmed: 16985875
Cancer Res. 2012 Feb 1;72(3):636-44
pubmed: 22144470
Genome Med. 2016 Jun 20;8(1):69
pubmed: 27323951
Sci Rep. 2017 Apr 05;7:45704
pubmed: 28378855
Science. 2013 Feb 22;339(6122):957-9
pubmed: 23348506
Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11
pubmed: 16341240
Oncogenesis. 2015 Dec 14;4:e176
pubmed: 26657580
Sci Rep. 2018 Apr 20;8(1):6339
pubmed: 29679052
J Clin Invest. 2019 Jan 2;129(1):223-229
pubmed: 30358567
Oncotarget. 2017 Aug 24;8(44):77540-77551
pubmed: 29100407
Mol Oncol. 2020 Oct;14(10):2358-2374
pubmed: 33245585
Genes Dev. 2015 Nov 1;29(21):2219-24
pubmed: 26515115
Nucleic Acids Res. 1989 Apr 11;17(7):2503-16
pubmed: 2785681
Lancet Oncol. 2013 May;14(6):534-42
pubmed: 23598174
Clin Res Hepatol Gastroenterol. 2015 Oct;39(5):600-9
pubmed: 25683523
Int J Cancer. 2019 Apr 1;144(7):1676-1684
pubmed: 30350309
Nature. 2003 Nov 13;426(6963):194-8
pubmed: 14608368
Nature. 1990 May 31;345(6274):458-60
pubmed: 2342578
Cell Rep. 2017 Dec 26;21(13):3700-3707
pubmed: 29281820